Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 1997

View Archived Issues

Titan's Spheramine receives orphan drug designation

Indomethacin prodrug with potent antiinflammatory effects, low ulcerogenicity

Microtubule inhibitor with low toxicity and unique profile of CaM activity

New D4 antagonist may aid in the search for antipsychotic drugs

PDGFr tyrosine kinase inhibitor with potential in atherosclerosis

New nonpeptide substance P antagonist from Pfizer

Antiinflammatory selectin-binding peptides from Affymax

Xoma discloses rBPI-Ig fusion proteins

AMBI acquires nutrition company

Martek oils shown effective in preterm infant nutrition

Rhone-Poulenc will increase its ownership of Rhone-Poulenc Rorer

Hoechst Marion Roussel reports new antiallergy agents

Vertex discloses a novel series of ICE inhibitors

Amgen acquires rights to FKBP-neuroimmunophilin ligands

RespiGam approved for marketing in Canada

Initial PURSUIT trial results presented in Stockholm

U.S. patent issued for Martek's ARA oil

Medtronic initiates U.S. clinical trials of beStent Rival

FDA approves Watson's estazolam

HemoCleanse receives NIH grant to develop bioartificial liver

Pace launches Cardiologic system

Ergo issued method-of-use patents for Ergoset

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...